TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01598883
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 U/kg
Study: NCT02873065
Drug: Esoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01082874
Drug: Placebo ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-op (goal 2-4 hours): 2 oral placebo tablets. Post-op: patients ingest one placebo tablet a day for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery
Study: NCT01194089
Drug: Nasal Normal Saline Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: An isotonic solution of sodium chloride 0.65% in deionized water
Study: NCT02514694
Drug: LEO32731
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00764387
Drug: Gadovist® (Gadobutrol, BAY86-4875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0,1 mmol/kg of body weight in the vein, single administration
Study: NCT00569244
Drug: Drug: YAZ flex (SH T00186D)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended flexible regimen of YAZ (SH T00186D); triggered by bleeding events(Tablet p.o. (oral))
Study: NCT00875238
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03691844
Drug: AMZ001
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac gel
Study: NCT03691844
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03691844
Drug: Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac gel
Study: NCT02563860
Drug: Lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dose escallating
Study: NCT00496392
Drug: Nasal fentanyl
Normalized name: fentanyl Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breakthrough pain in patients with breast or prostate cancer
Study: NCT03371563
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were treated with antibiotics for Lyme disease.
Study: NCT04392141
Drug: Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine plus a Herbal extraction containing a Phenolic Monoterpene Fractions will be added to standard treatment in patients with COVID-19.
Study: NCT03910738
Drug: Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (Nebido® Testosterone Undecanoate ) will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)
Study: NCT03910738
Drug: Placebo 4 mL Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be injected at Baseline, at week 6 and then every 12 weeks (Week 18, 30, 42 and 54)
Study: NCT01425450
Drug: HF1020
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses at 0.5 mg capsules, 2.5 mg capsules, 10 mg capsules, and 25 mg capsules in each of cohorts 1, 2, 3 and 4 respectively.
Study: NCT01425450
Drug: HF1020 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose: HF1020 placebo capsule
Study: NCT04452435
Drug: C21
Normalized name: C18-C21 alkane
Approvals — FDA: no, EMA: no, PMDA: no
Description: C21
Study: NCT04452435
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03399955
Drug: Paromomycin
Normalized name: Paromomycin
DrugBank: Paromomycin (DB01421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paromomycin (20 mg/kg/d) IM for 14 days
Study: NCT00746174
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1 tablet PO daily for 16 weeks
Study: NCT03677466
Drug: Pharmaco-invasive strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient with primary STEMI will received standard doses of fibrinolytics with following PCI.~After reperfusion strategies will be conducted cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images, T1-weighted images. and Global Longitudinal Strain measured with echocardiography.
Study: NCT03793439
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taper corticosteroids starting at week 4
Study: NCT03244059
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An identically appearing placebo infusion.
Study: NCT01344967
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic Acid at a dose of 4mg will be administered by intravenous infusion over 15 minutes in at least 100mls of saline
Study: NCT00595231
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg tablets
Study: NCT01341457
Drug: LY2603618
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT02502669
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00273520
Drug: Telithromycin
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00600171
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo mulit-dose dry powder inhaler
Study: NCT02421887
Drug: Antioxidant Supplement
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine
Study: NCT02104414
Drug: Bupivacaine HCl with Epinephrine
Normalized name: Bupivacaine Hydrochloride/Epinephrine 0.25%-1:200000 Injection Solution [BUPIVACAINE HCL WITH EPINEPHRINE NOVAPLUS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75mg/30mL 0.25% Bupivacaine HCl with epinephrine
Study: NCT02104414
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30mL Normal Saline
Study: NCT00103012
Drug: Gingko Biloba
Normalized name: Gingko Biloba
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo Biloba 120 mg twice daily for 14 days
Study: NCT02048345
Drug: Suspension Fed State
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02048345
Drug: Solution Fed State
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01418131
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02959827
Drug: Iodinated contrast agents
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of iodine contrast agents and doses following the decision of the treating physician.
Study: NCT01259648
Drug: 0.5 µg/kg remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 µg/kg remifentanil is used during induction in addition to the classic induction protocol
Study: NCT01259648
Drug: 1.0 µg/kg remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 µg/kg remifentanil is added to the classic induction anesthesia protocol
Study: NCT01920568
Drug: Zoledronic acid 4 mg
Normalized name: zoledronic acid 4 MG
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 4 mg (or equivalent clearance-adjusted dose in subjects with baseline creatinine clearance \<=60 ml/min) will be diluted in either 0.9% sodium chloride or 5% dextrose injection and administered IV.
Study: NCT01920568
Drug: Placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will consist of 1.7 mL 0.9% w/v sodium chloride
Study: NCT01920568
Drug: Placebo SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will consist of either 0.9% w/v sodium chloride or 5% dextrose injection
Study: NCT00003603
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003603
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04072601
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose monohydrate 50 mg, potato starch 45 mg, Gelatine 1,2 mg, Magnesium stearate 0,5, Talc 4,5 mg
Study: NCT03256903
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any kind of analgesia, administered by any route for emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain
Study: NCT00883870
Drug: Plasmalyte A
Normalized name: PLASMALYTE A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection
Study: NCT04290793
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m\^2 d1 iv Q2W for 4 cycles
Study: NCT04290793
Drug: Taxanes
Normalized name: Taxanes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin paclitaxel（125mg/m2 d1、8 iv Q3W for 4 Cycles）/Docetaxel(100mg/m2 d1 iv Q3W for 4 Cycles )
Study: NCT00405964
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet, once daily for 12 weeks
Study: NCT01357135
Drug: Sulfonylurea
Normalized name: Sulfonylurea
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01357135
Drug: Antihyperglycemic Medication
Normalized name: ANTIHYPOGLYCEMICS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01144975
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile solution, SC injections administered by study personnel (the subject will receive a total of 8 injections)
Study: NCT00008190
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01505894
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT00788320
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo three times a week for 8 weeks
Study: NCT01846663
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, oral, 0 mg BID, 6 months of treatment
Study: NCT01371812
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be orally administered to 4 subjects in each treatment period of each cohort.
Study: NCT05174195
Drug: Implanon NXT® subdermal implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inserted immediately
Study: NCT05596617
Drug: Oral bedtime melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different doses of oral bedtime melatonin
Study: NCT00888329
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02051153
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02931929
Drug: 68Ga-NeoBOMB1, 2-vial kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous application of a radiopharmaceutical for Positron Emission tomography (PET)
Study: NCT03085628
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40IU
Study: NCT04286841
Drug: Immunotherapy
Normalized name: Dog immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in this group should be histologically confirmed potentially resectable NSCLC with stage II-IIIA. Furthermore patients would receive either single agent immunotherapy or immunotherapy combined with chemotherapy.
Study: NCT02313870
Drug: clobetasol propionate + Methotrexate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: daily applications of topical clobetasol propionate at a dose of 10 to 30 g / day depending on the patient's weight and the initial number of new blisters per day, associated with methotrexate (MTX) received either orally or subcutaneously at a dose of 12.5 mg / week in patients weighing less than 60 kg and with creatinine clearance greater than 50 ml / min (planned dose reduction to 10 mg / week in patients less than 60 kg or with a creatinine clearance less than 50 ml / min) for four weeks followed by oral or subcutaneous methotrexate alone at the same dose during following 8 months
Study: NCT02210689
Drug: clindamycin phosphate vaginal cream 2%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01377987
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg, once daily before bed, for 7 days
Study: NCT01736904
Drug: wXELIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: irinotecan 90mg/m2 D1, capecitabine 1000mg/m2 bid po, D1-5,repeated every 7 days
Study: NCT01736904
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks
Study: NCT00744978
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 1 week followed by placebo twice daily for 5 weeks.
Study: NCT01000922
Drug: Regular Human Insulin
Normalized name: insulin, regular, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual dose of RHI administered subcutaneously
Study: NCT01000922
Drug: VIAject
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual dose of VIAject administered subcutaneously
Study: NCT01000922
Drug: VIAject 50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual dose of VIAject 50% administered subcutaneously
Study: NCT04000308
Drug: Wound Infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 20 ml levobupivacaine 0.25% infiltration in the surgical wound and US-guided QLB with 30 ml normal saline bilaterally (60 ml in total).
Study: NCT03587025
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00511043
Drug: PTK787
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTK787 - 1250mg p.o. daily. Initial dose of 750mg p.o daily starting on day 1 and increased weekly to an intermediate dose of 1000 mg and then a target dose of 1250mg unless a grade ≥ 2 toxicity. Patients who tolerate the study target dose of 1250mg will remain on that dose until study completion at 12 months or until disease progression, unacceptable toxicity, withdrawal of consent or patient non-compliance with the protocol requirement.
Study: NCT00603239
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection, volume equivalent to 5 mcg or 10 mcg of active drug, twice a day
Study: NCT02095665
Drug: Tylenol #3
Normalized name: Tylenol #3 Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tab of Tylenol #3 every 6 hours as necessary from stent insertion until removal 5 to 10 days
Study: NCT00223977
Drug: Oral Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg ferrous sulfate orally three times daily x 8 weeks
Study: NCT03822455
Drug: OligoG DPI
Normalized name: capryl oligoglucoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: OligoG Dry Powder for Inhalation
Study: NCT02359045
Drug: D1400147
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A
Study: NCT02359045
Drug: D14000136
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B
Study: NCT02359045
Drug: D14000137
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C
Study: NCT02359045
Drug: Epanova®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment D
Study: NCT03479294
Drug: Shenlingcao Oral Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenlingcao Oral Liquid is a health product, and its main components are American ginseng, lucidum, Cordyceps fermented powder Cs-4, rose, maltitol and water. Shenlingcao Oral Liquid can relieve physical fatigue and enhance immunity.
Study: NCT02708849
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral dose placebo
Study: NCT00904098
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current treatment used to treat all migraine headaches
Study: NCT01588314
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: compounded placebo capsules
Study: NCT01190254
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: asenapine-matched placebo tablets for sublingual administration
Study: NCT02493257
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01303146
Drug: rhARSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion 100U/kg every other week for 18 months
Study: NCT01456208
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A hormone that is normally present in your body, which regulates your blood pressure.
Study: NCT02655523
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of preservative free normal saline
Study: NCT03515551
Drug: IMCnyeso
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly IV infusions of IMCnyeso
Study: NCT04170504
Drug: Qing Re Huo Xue (QRHX) granule
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qing Re Huo Xue (QRHX) granule 10g bid for 24 weeks
Study: NCT04170504
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate 10 mg per week for 24 weeks.
Study: NCT04170504
Drug: Qing Re Huo Xue (QRHX) granule placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qing Re Huo Xue (QRHX) granule placebo 10g bid for 24 weeks
Study: NCT01391572
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00907530
Drug: MULTIHANCE:
Approvals — FDA: no, EMA: no, PMDA: no
Description: MULTIHANCE ® 0.5 M,0.1 mmol/kg
Study: NCT00530829
Drug: zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 day blister pack of 20 mg zinc disperable tablets, 1 tablet qd for children 6 months to 4 years, 1/2 tablet qd for children 2-5 months
Study: NCT00143702
Drug: Riboflavin and Thiamine (Supplementation)
Normalized name: niacin / riboflavin / thiamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Detailed Description.
Study: NCT01115894
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01986309
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Chloride 0.9% infusion
Study: NCT00763685
Drug: etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 120 mg, paracetamol 1 g
Study: NCT03597529
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: melatonin
Study: NCT03972345
Drug: Norditropin® FlexPro®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with commercially available Norditropin® FlexPro® according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available Norditropin® FlexPro® has been made by the treating physician and the patient's parents/legal guardian before and independently of the decision to include the patient in this study.
Study: NCT03648489
Drug: TAK228
Approvals — FDA: no, EMA: no, PMDA: no
Description: Please refer to arm/group description
Study: NCT02298179
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of 0.5 milliliters (mL) each of injectable solution administered intramuscularly, in the deltoid muscle, preferably in the non-dominant arm.
Study: NCT03628144
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care: Chemotherapy as already planned for each participant.
Study: NCT03836833
Drug: ABC/3TC/LPV/r granules (30/15/40/10 mgs)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a fixed dose combination. Each capsule contains Lopinavir (40mg), Ritonavir (10mg), Abacavir (30mg) and Lamivudine (15mg) in granules formulation.~Dosage according to patient's weight:~Between 3 and 5.9kg: 2 capsules twice a day Between 6 and 9.9kg: 3 capsules twice a day Between 10 and 13.9kg: 4 capsules twice a day Between 14 and 19.9kg: 5 capsules twice a day Between 20 and 24.9kg: 6 capsules twice a day
Study: NCT03836833
Drug: LPV/r Pellets (40/10mgs) plus ABC/3TC (60/30mgs)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg dispersible tablets)~Dosage according to patient's weight:~LPV/r Pellets:~Between 3 and 5.9kg: 2 capsules twice a day Between 6 and 9.9kg: 3 capsules twice a day Between 10 and 13.9kg: 4 capsules twice a day Between 14 and 19.9kg: 5 capsules twice a day Between 20 and 24.9kg: 6 capsules twice a day~ABC/3TC:~Between 3 and 5.9kg: 1 tablet twice a day Between 6 and 9.9kg: 1.5 tablets twice a day Between 10 and 13.9kg: 2 tablets twice a day Between 14 and 19.9kg: 2.5 tablets twice a day Between 20 and 24.9kg: 3 tablets twice a day
Study: NCT00737568
Drug: FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emtricitabine (FTC)/TDF 200/300 mg fixed-dose combination tablet administered orally once daily
Study: NCT00737568
Drug: TDF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF placebo tablet administered orally once daily
Study: NCT00737568
Drug: FTC/TDF Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTC/TDF placebo tablet administered orally once daily
Study: NCT00656188
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT00704483
Drug: SBR759
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose of 1g or 1.5g tid, with an increase of 1g tid every 2 weeks until serum phosphate level fall below target.
Study: NCT00704483
Drug: SBR759
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g tid
Study: NCT00380991
Drug: lactoserum
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01743235
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)
Study: NCT01743235
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solid Oral Dosage. Maximum every other day (on an as needed basis)
Study: NCT02213848
Drug: Calcium
Normalized name: Calcium
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of calcium chloride 5 mg/kg along with neostigmine 25 mcg/kg + atropine 15 mcg/kg
Study: NCT02966964
Drug: DWPUR001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02966964
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02626234
Drug: INC280
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02626234
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02472418
Drug: DFN-15 Dose B (treatment B)
Normalized name: sennoside B 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFN-15 Dose B administered